Physician profile
Chad Collom
NPI 1396906285
$2,017.89
in general payments reported to CMS, 2019-2025
22 companies · $559 in 2025
The $559 reported for 2025 was more than what a typical Psychiatric/Mental Health (Nurse Practitioner) provider received nationally (typical 2025 total: $257).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $284 · 2022: $203 · 2023: $259 · 2024: $713 · 2025: $559.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,531.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,530.83 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $632.35 | 2021-2025 | Caplyta |
| Axsome Therapeutics, INC. | $178.85 | 2024-2025 | Auvelity |
| Takeda Pharmaceuticals U.S.A., INC. | $174.30 | 2021-2025 | Trintellix |
| Tris Pharma INC | $168.96 | 2021-2024 | Dyanavel Xr |
| Janssen Pharmaceuticals, INC | $149.74 | 2022-2025 | Spravato |
| Otsuka America Pharmaceutical, INC. | $114.11 | 2021-2025 | Rexulti |
| Bausch Health US, LLC | $113.65 | 2021-2025 | Aplenzin, Wellbutrin |
| Corium, LLC | $111.56 | 2024-2025 | Azstarys |
| Sunovion Pharmaceuticals INC. | $84.37 | 2021-2022 | |
| Abbvie INC. | $67.32 | 2021-2025 | |
| Alkermes, INC. | $39.26 | 2023-2024 | Aristada, Lybalvi |
| Supernus Pharmaceuticals, INC. | $21.63 | 2023 | Qelbree |
| Merck Sharp & Dohme LLC | $19.72 | 2023 | Belsomra |
| Almatica Pharma LLC | $18.47 | 2021 | |
| Orexo US, INC. | $17.52 | 2024 | Zubsolv |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Jazz Pharmaceuticals INC. | $17.00 | 2021 | |
| Idorsia Pharmaceuticals US INC | $16.73 | 2024 | Quviviq |
| Teva Pharmaceuticals USA, INC. | $16.64 | 2023 | Austedo Xr |
| Vertical Pharmaceuticals, LLC | $14.72 | 2024 | Relexxii |
| Neurocrine Biosciences, INC. | $14.32 | 2022 | |
| Collegium Pharmaceutical, INC. | $13.51 | 2025 | Jornay Pm |
| Ironshore Pharmaceuticals INC. | $13.16 | 2023 | Jornay Pm |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Chad Collom listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.